Repligen (RGEN) Company Overview

Repligen (RGEN) experienced a significant rise in its stock price during the last trading session, with trading volume exceeding the usual amount. However, the recent changes in earnings estimates might not lead to a further increase in the stock price in the short term.

WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a company specializing in bioprocessing technology, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, taking place from January 13 to 16 in San Francisco. Olivier Loeillot, the President and CEO, will give a presentation about the company on Tuesday, January 14 at 1:30 p.m. PT.

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a company specializing in life sciences and bioprocessing technology, has announced the launch of its CTech™ SoloVPE® PLUS System. This system is the latest and most advanced UV-based Variable Pathlength Technology available for biopharmaceutical manufacturers.

WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a company specializing in bioprocessing technology, has released its 2023 Corporate Sustainability Report. Titled “Advancing Impacts,” the report highlights the company's efforts in sustainability across six main areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Partnerships & Pathways. It also includes detailed information that aligns with four major reporting frameworks: the Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UN SDGs), and Task Force on Climate-Related Disclosures (TCFD).

Repligen (RGEN) shared its earnings report 30 days ago. What can we expect for the stock moving forward?

New advancements have been made in the purification of mRNA therapeutics and vaccines. These innovations aim to improve the quality and effectiveness of these treatments. This progress is significant for the development of future medical solutions.

Repligen Corporation (NASDAQ:RGEN) held its Q3 2024 earnings conference call on November 12, 2024, at 8:30 AM ET. The call featured company representatives, including Sondra Newman, Olivier Loeillot, and Jason Garland, as well as analysts from various financial institutions. The operator welcomed everyone to the call, marking the start of the discussion.

RGEN has announced third-quarter results that exceeded expectations. Although the management has reduced its sales forecast for 2024, they have increased their earnings per share (EPS) outlook.

Repligen Corp (RGEN) announced on Tuesday that its adjusted earnings per share for the third quarter were 43 cents, an increase from 23 cents last year, and higher than the expected 33 cents.